The US government's plans to end the pay-for-delay agreements between pharmaceutical and generic companies has been criticised

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.623, 2011-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The US Supreme Court has said it will consider the legality of pay for delay agreements

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 669, 2013-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

New legislation aimed at severing the close ties between the US FDA and drug companies has been introduced in the US.

By  

Inpharma, Vol. 1, Iss. 1488, 2005-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

The US FDA has been criticised for its handling of the investigation into the contaminated heparin crisis.

By  

Reactions Weekly, Vol. 1, Iss. 1329, 2010-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Teva Pharmaceutical Industries has decided not to sell generic Lipitor [atorvastatin] in the US

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 655, 2012-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Funding in the amount of $US1 million has been pledged by US-based pharmaceutical giant Wyeth

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 365, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite